Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

TARGETED THERAPHY

EGFR blockade activates interferon

Nature Cancer volume 1, pages 376–378 (2020)Cite this article

Subjects

Dysregulation of innate immune signaling in cancer can be pro-tumorigenic and can promote adaptive resistance to targeted therapies. Type I interferon signaling is now shown to promote survival following inhibition of the kinase EGFR, even in cells that are not ‘addicted’ to EGFR signaling.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Inhibition of EGFR triggers an adaptive innate immune response.

References

  1. Zhang, Y. L. et al. Oncotarget 7, 78985–78993 (2016).

    PubMed  PubMed Central  Google Scholar 

  2. Yu, H. A. et al. Clin. Cancer Res. 19, 2240–2247 (2013).

    Article  CAS  Google Scholar 

  3. Soria, J. C. et al. N. Engl. J. Med. 378, 113–125 (2018).

    Article  CAS  Google Scholar 

  4. Piotrowska, Z. et al. Cancer Discov. 8, 1529–1539 (2018).

    Article  Google Scholar 

  5. Le, X. et al. Clin. Cancer Res. 24, 6195–6203 (2018).

    Article  Google Scholar 

  6. Sequist, L.V. et al. Lancet Oncol. 21, 373–386 (2020).

    Article  CAS  Google Scholar 

  7. Lee, H. J. et al. Cancer Cell 26, 207–221 (2014).

    Article  CAS  Google Scholar 

  8. Blakely, C. M. et al. Cell Reports 11, 98–110 (2015).

    Article  CAS  Google Scholar 

  9. Terai, H. et al. Cancer Res. 78, 1044–1057 (2018).

    Article  CAS  Google Scholar 

  10. Gong, K. et al. Nat. Cancer https://doi.org/10.1038/s43018-020-0048-0 (2020).

    Article  Google Scholar 

  11. Vanpouille-Box, C., Demaria, S., Formenti, S. C. & Galluzzi, L. Cancer Cell 34, 361–378 (2018).

    Article  CAS  Google Scholar 

  12. Ivashkiv, L. B. & Donlin, L. T. Nat. Rev. Immunol. 14, 36–49 (2014).

    Article  CAS  Google Scholar 

  13. Barbie, D. A. et al. Nature 462, 108–112 (2009).

    Article  CAS  Google Scholar 

  14. Gainor, J. F. et al. Clin. Cancer Res. 22, 4585–4593 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Ryohei Yoshida & David A. Barbie

  2. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA

    David A. Barbie

Authors
  1. Ryohei Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Barbie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Barbie.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshida, R., Barbie, D.A. EGFR blockade activates interferon. Nat Cancer 1, 376–378 (2020). https://doi.org/10.1038/s43018-020-0055-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-020-0055-1

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer